Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the entry into definitive agreements for the exercise of certain outstanding preferred investment options to ...

The DoD award will support a three-year study of intranasal anti-CD3 in the acute phase of SCI, aimed at patients who present to the hospital immediately following injury. Complementing this, a ...

The poster presentation can be found on Alterity’s website here.

Revised label allows treatment of DEB patients from birth. VYJUVEK can now be applied by patients and caregivers . PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, ...

Partnership strengthens Nugevia™ launch bringing clinical and scientific integrity to the fast-growing longevity space ...

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced a poster ...

(GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of its investigational small ...

Under a pre-existing license agreement, Sichuan Haisco Pharmaceuticals retains rights to frunexian in China, having completed a successful Phase 1 trial there. Under the terms of the license, Cadrenal ...

SPY072 is a potential first- and best-in-class anti-TL1A antibody for rheumatic diseases targeting quarterly or twice-yearly subcutaneous dosing. SKYWAY study is evaluating SPY072 ...

Our second quarter results reflect strong sales growth for the SynCardia total artificial heart,” said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical. “We achieved over 200% ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a licensing agreement with Kwangdong Pharmaceutical, ...

Harrow’s Investor & Analyst Day will include a comprehensive overview of Harrow’s business, featuring presentations from the Company’s leadership team covering the full scope of Harrow’s commercial ...